What is it about?
Colorectal cancer (CRC) is one of the main causes of cancer-related death in developed countries. Targeted therapies and conventional chemotherapeutics have been developed to help treat this type of aggressive cancer. Liposomes and immunoliposomes are under intensive investigation as pharmaceutical nanocarriers and can be functionalized with specific antibodies. We showed that liposomes loaded with a specific proteasome inhibitor (LLNle) were more effective in inducing cancer cell death with respect to immuno-liposomes conjugated with a specific antibody against ERBB1 (Cetuximab), probably due to lysosomal inactivation.
Featured Image
Photo by National Cancer Institute on Unsplash
Why is it important?
Colorectal cancer (CRC) is one of the main causes of cancer-related death in developed countries. Targeted therapies and conventional chemotherapeutics have been developed to help treat this type of aggressive cancer. The development of immuno-liposomes that may specifically target cancer cells and deliver a therapeutic drug is an important way to fight cancers limiting drug-indiced side-effects.
Read the Original
This page is a summary of: Liposomes Loaded with the Proteasome Inhibitor Z-Leucinyl-Leucinyl-Norleucinal Are Effective in Inducing Apoptosis in Colorectal Cancer Cell Lines, Membranes, May 2020, MDPI AG,
DOI: 10.3390/membranes10050091.
You can read the full text:
Contributors
The following have contributed to this page
